Videos

High-risk patient populations for pneumococcal pneumonia are discussed by Christina Madison, PharmD, FCCP, AAHIVP.

Key opinion leaders discuss factors leading to the development of novel pneumococcal vaccines.

Experts examine the yearly modifications in the formulations of flu vaccines and explore the variations in the adverse events experienced across different types of flu vaccines.

Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.

Experts navigate the impact of proteasome inhibitors and anti-CD38 antibody therapies in the relapsed refractory multiple myeloma treatment landscape.

Experts highlight the use of 3- and 4-drug regimens for managing relapsed refractory multiple myeloma.

The panel explores RSV infection susceptibility and transmission.

Community health worker training can allow the technician to perform to the top of their abilities and improve access to the pharmacy’s public health services.

Key opinion leaders discuss risk factors for RSV and patient populations most susceptible to the disease.

COVID-19 is helping to shape current pharmacy practice, including increased vaccinations, access to care, and better interactions with patients.

An expert panel discusses the development of recombinant and cell-based vaccines and new types of influenza vaccines being explored.

Experts review how influenza vaccines have advanced in recent years and discuss misconceptions that people may have about standard-dose and high-dose flu vaccines.

Medical experts provide an overview of the signs and symptoms of pneumococcal infections.

Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.

Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.

Ryan Haumschild, PharmD, MS, MBA, leads a panel of medical experts in a discussion regarding adult RSV vaccination.

During the pandemic, many community pharmacists also gained the authority to provide routine vaccinations for child populations.

Liam Volk, MPharm, discussed the recent end of the FDA’s ban on gay and bisexual men donating blood, saying it’s a good step, although more must be done.

Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.

Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.

Health Mart is offering a new basic training program with ASHP/ACPE accreditation for pharmacy technicians, along with accredited and non-accredited training.

Christina Madison, PharmD, FCCP, AAHIVP, sat down with Sandra Leal, PharmD, MPH, FAPhA, CDCES, vice president of pharmacy practice innovation and advocacy at CVS Pharmacy, to discuss how pharmacists are diving into public health and expanding their roles.

Approximately 50% of patients with refractory or relapsed disease achieved complete response following treatment with the Janus kinase 1 (JAK1) inhibitor.

Liam Volk, MPharm, president-elect of the Pharmacists’ Defence Association LGBT+ Network, discussed how pharmacists can best support their LGBTQ+ colleagues and patients.

Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.

Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.

Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.